Industria y Comercio
SUPERINTENDENCIA

Prosperidad para todos

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO	
RAD: 11-82861- -11	**FECHA**: 2013-08-30 14:42:58
DEP: 2020 DIRECCION DE NUEVAS CREACIONES	**EVE:** 378 FASE NACIONAL INCLUIDO CAPITULO I
TRA: 11 PCT-PATENTE DE INVENCION CAPITULOS I Y II	**FOLIOS**: 6
ACT: 519 PRESENTACION	

DIRECCIÓN DE NUEVAS CREACIONES

2020
Bogotá, D.C.,

Abogado(a)/Señor(a)
ANDREA TOBOS MATEUS

Asunto: Radicación: 11-82861- -11
Trámite: 11
Evento: 378
Actuación: 519
Oficio: 16325
Folios: 6

Patente de Invención	X			Patente de Modelo de Utilidad	
Vía Nacional					
Vía PCT (Fase Nacional)	X	Capítulo I	X	Capítulo II	
No. Solicitud Internacional	PCT/US2009/066459				
Fecha de Presentación Internacional	02/12/2009				

Jurídicos:

Mediante oficio Nº 23240 notificado por fijación en lista de fecha 26 de diciembre del 2012, este Despacho requirió a la doctora Andrea Tobos Mateus, en los términos del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, para que dentro del plazo de sesenta días presentara respuesta a las observaciones de carácter técnico, relacionadas con la patentabilidad o cumplimiento de los requisitos establecidos por esta Decisión, para la concesión de la patente que se tramita dentro del expediente de la referencia.

Teniendo en cuenta que este Despacho realizó la determinación del estado de la técnica de acuerdo con la fecha de reivindicación de prioridad US 61/119,723 del 03 de diciembre de 2009, sin que hubiera lugar a ello puesto que la materia técnica de la solicitud en estudio no está divulgada en la solicitud de prioridad mencionada, y adicionalmente se referencia como Documento D1 la publicación de patente US2008/058393 cuyo título es “Fungicidal Detergent Compositions” cuando en realidad el documento pertinente para realizar el examen de patentabilidad es la publicación WO2008/021927 titulada “Hepatitis C Virus Inhibitors”, con lo cual se configura un traslado del estado de la técnica inadecuado por error en la fecha establecida para la determinación del estado de la técnica y en los documentos reportados como cercanos a la materia reivindicada, por lo tanto es procedente revocar en su totalidad el oficio Nº 23240 de fecha 26 de diciembre del 2012 y en su lugar efectuar un nuevo requerimiento a su nombre, en los siguientes términos:

Como resultado del examen de fondo, realizado conforme a lo establecido por el artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le comunica:

1. Documentos estudiados

Descripción:	Radicado 11-082861-00000-0000	01/julio/2011
	Radicado 11-082861-00004-0000	05/agosto/2011
Reivindicaciones:	Radicado 11-082861-00000-0000	01/julio/2011
	Radicado 11-082861-00004-0000	05/agosto/2011
	Radicado 11-082861-00010-0000	15/mayo/2013
Respuesta de la solicitante:	Radicado 11-082861-00010-0000	15/mayo/2013
Prioridades:	US 61/119,723	30/diciembre/2008
	US 61/173,590	28/abril/2009
	US 61/214,881	28/abril/2009
	US 61/182,952	01/junio/2009
	US 61/182,958	01/junio/2009

2. Análisis de la Prioridad

Se aceptan las reivindicaciones de prioridades US 61/214,881 del 28 de abril 2009 y US 61/182,958 del 01 de junio del 2009 porque ésta solicitud fue presentada dentro del plazo establecido (Art. 9 D 486) y su contenido técnico corresponde con el de las prioridades reivindicadas.

Las reivindicaciones de las prioridades US 61/119,723 del 03 de diciembre de 2009, US 61/173,590 del 28 de abril 2009 y 61/182,952 del 01 de junio del 2009 no se aceptan porque las mismas hacen referencia a compuestos de fórmula  y la solicitud en estudio refiere compuesto de fórmula  y no ejemplifican ningún compuesto que presente el grupo anillo biciclo BB´ cuando W y A son los sustituyentes definidos en el solicitud en estudio.

3. Objeto de la invención

De acuerdo con lo establecido en el numeral 1.2.2.2 del capítulo primero del Título 10 de la Circular Única para efectos del examen de patentabilidad, se tendrá en cuenta la tasa pagada por el solicitante al momento de comenzar el examen para las reivindicaciones adicionales; esto es que cuando la solicitud contenga más de diez (10) reivindicaciones y no se haya pagado la tasa complementaria, sólo se estudiarán las cubiertas por la tasa pagada. Por tal motivo, y teniendo en cuenta la tasa pagada por el solicitante, se estudiará la totalidad del capítulo reivindicatorio presentado bajo radicado N° Radicado 11-082861-00010-0000 aceptando la modificación efectuada por el solicitante.

Título de la solicitud: “INHIBIDORES DE HCV NS5A”

El problema planteado en esta solicitud consiste en la necesidad de diseñar suministrar compuestos útiles inhibir la replicación del virus de la hepatitis C (HCV), particularmente funciones de la proteína 5a no estructural (NS5A)

Para resolver este problema técnico la solicitud en estudio proporciona un compuesto de la fórmula (I) y composiciones que lo contienen.


Compuesto (I)

El objeto de la presente solicitud se relaciona con la Clasificación Internacional de Patentes (CIP): A1N 43/50 // 43/52 y A61K 31/415.

4. De la solicitud de patente

Titulo

El título no corresponde con el objeto de la solicitud porque no define la naturaleza de los compuestos reclamados, por lo cual se sugiere al solicitante hacer la corrección necesaria.

Reivindicaciones (Art 30 D 486, Art 22 PCT)

El capítulo reivindicatorio no es conciso por cuanto los términos alquilo, arilo, cicloalquilo, heteroarilo, heterocíclico, aralquilo, heterociclilalquilo y aminoácidos indicados para cada uno de los sustituyentes son definidos de manera funcional y no definen indistintamente la materia reivindicada, al señalar un número indefinido de compuestos que no encuentran soporte en la descripción. Por ejemplo para cicloalquilo no se definen los números de átomos que lo conforman, o para los términos arilo o heteroarilo, heterociclo, aralquilo, aralquenilo, heterociclilalquilo, heteroaril alquilo, no se define el número de átomos de carbono o de miembros que conforman los anillos, si es monocíclico o bicíclico, y en el caso de hetero no se definen los posibles heteroátomos que los pueden conformar. Es así como, de acuerdo a los ejemplos que soportan la descripción, se encuentra:

- B y B´ corresponden en su mayoría a anillo de 6 miembros aromáticos.
- W corresponde en su mayoría a fenilo.
- A´ corresponde en su mayoría a imidazol.

Por esta razón, se sugiere al solicitante definir términos precisos acerca de la naturaleza y tamaño de los sustituyentes del compuesto reivindicado y restringir la solicitud a una razonable generalización del tipo de compuestos que ha sido sintetizado ó probado, es decir, que se encuentran debidamente sustentados.

5. Determinación del Estado de la Técnica

El estado de la técnica se determinó con base en la fecha de presentación de la solicitud de prioridad más antigua aceptada: abril 28 de 2009 y se encontraron los siguientes documentos que anticipan el objeto de esta solicitud:

Ítem	Documento	Título	Fecha de Publicación*
D1	WO 2008 021927	“Hepatitis C Virus Inhibitors ”	21/febrero/2008
D2	Medicinal Chemistry, 2008, 4, 605-615	“2-Arylbenzimidazoles as Antiviral and Antiproliferative Agents-Part 1”	Noviembre/2008

El documento D1 [1] divulga compuestos útiles para el tratamiento de la hepatitis C de fórmula I, inhibidores de función de la proteína HCV NS5A (Fl. 272, líneas 4-5)


Compuesto I (Fl. 3, líneas 24-25)

1: http://www.google.com/patents/WO2008021927

El documento D2 [2] divulga estrategias para el desarrollo de nuevos agentes antivirales (Pág. 3, párrafo 2)

6. **Examen de Patentabilidad** (Art 14 D286)

Nivel inventivo (Art18 D286)

La reivindicación 1 consiste en: un compuesto de fórmula I



Compuesto (I)

Comparación de las características técnicas esenciales, con las del Estado de la Técnica

Características esenciales	D1	D2
Un compuesto de fórmula I  Compuesto I	Un compuesto de fórmula I  Compuesto I (Fl. 3, líneas 24-25)	Divulga estrategias para el desarrollo de nuevos agentes antivirales que incluyen entre otras la modificación del conector (Linker) (Pág. 3, párrafo 2)   Estructura general de las estructuras diseñadas
Realizaciones preferidas	**Compuestos específicos**	**Compuestos específicos**
 Compuesto 2 (Fl.336, tabla 1)  Compuesto 1 (Fl.336, tabla 1)  Compuesto 74 (Fl.349, tabla 1)	 Compuesto 153 c (Fl.367, tabla 1)  Compuesto F62 (Fl.413,)	 Compuesto 6 (Pág. 606, fig. 3)  Compuesto 8 (Pág. 606, fig. 3)
 Compuesto 5 (Fl.129, esquema 6-5)	 Compuesto 1 (Fl.144, líneas 15-18)  Compuesto M104 (Fl.616, líneas 1-5)	 Compuesto 9 (Pág. 606, fig. 3)

2: http://www.ncbi.nlm.nih.gov/pubmed/18991746

El documento D1 se consideran el estado de la técnica cercano a lasolicitud en estudio definida en la reivindicación 1 porque divulga inhibidores de función de la proteína HCV NS5A caracterizados porque presentan dos residuos 2-(1-acetilpirrolidin-2-il)-1*H*-imidazol-4-il que se encuentra conectado a través de un grupo bifenilo o biazaheteroarilo de 6 miembros o fenilo-azaheteroarilo de 6 miembros.

La diferencia entre la solicitud, definida en la reivindicación 1 y los compuesto del documentos D1 consiste en que la solicitud define que el grupo conector entre los dos residuos 2-(1-acetilpirrolidin-2-il)-1*H*-imidazol-4-il corresponde a secuencias como (arilo o azaheteroarilo)-biciclo o biciclo-biciclo donde uno de los biciclos proviene de la fusión de arilo con el anillo imidazol para formar un benzimidazol sus combinaciones entre tanto el documento D1 enseña que el grupo conector corresponde a dos anillos arilo o heteroarilo de 6 miembros.

El efecto que logra el modificar el grupo conector entre los dos residuos 2-(1-acetilpirrolidin-2-il)-1*H*-imidazol-4-il es que obtener nuevos compuestos alternativos inhibidores de función de la proteína HCV NS5A.

Por lo tanto, el problema técnico objetivo que pretende resolver esta invención se puede formular así: “cómo modificar el grupo conector entre los dos residuos 2-(1-acetilpirrolidin-2-il)-1*H*-imidazol-4-il de los compuestos del documento D1 para obtener nuevos compuestos alternativos inhibidores de función de la proteína HCV NS5A”.

Sin embargo, el documento D2 divulga estrategias para el desarrollo de nuevos agentes antivirales que incluyen entre otras: la modificación de los conectores (linkers) entre dos residuos que presenta la actividad antiviral, y enseña que entre los conectores utilizados se incluyen los grupos 4-difenilos sustituidos o α-naftil. Adicionalmente, ejemplifica que el tamaño del conector puede variar sin afectar considerablemente la actividad antiviral de los compuestos obtenidos, de donde una persona del oficio concluiría el remplazo de un grupo arilo o heteroarilo por un grupo α-naftil o una serie bioisóstera estaba sugerida por el documento D2 y por lo tanto no tiene nivel inventivo.

En consecuencia, la persona del oficio normalmente versada en la materia estaría motivada a modificar el grupo conector entre los dos residuos 2-(1-acetilpirrolidin-2-il)-1*H*-imidazol-4-il de los compuestos divulgados en el documento D1 de la manera que lo sugiere el documento D2 para llegar así al objeto de la reivindicación 1 de la solicitud. Por lo cual se considera obvia.

Puesto que las reivindicaciones dependientes 2-38 no mencionan características inventivas adicionales tampoco se pueden considerar inventivas.

7. Conclusión

Los requisitos de Patentabilidad de la presente solicitud están afectados así:

Ítem	Documento	Reivindicaciones afectadas	Requisito que afecta
D1	WO 20080021936	1-38	Nivel inventivo
D2	Medicinal Chemistry, 2008, 4, 605-615	1-38	Nivel inventivo

En cumplimiento del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le indica que debe dar respuesta dentro del término de sesenta (60) días contados a partir de la fecha de notificación de la presente comunicación. En caso de no dar respuesta al presente requerimiento, o si a pesar de la respuesta subsistieran los impedimentos para la concesión, se denegará la patente.

Se invita al solicitante se sirva indicar, si así lo considera, su renuncia al término faltante de sesenta (60) días para dar respuesta a este requerimiento y presentarla por escrito.

Finalmente, se le recuerda al solicitante que si como respuesta a este requerimiento llegara a modificar el capítulo reivindicatorio y éste contenga más de diez (10) reivindicaciones, no pagará la tasa de modificación voluntaria pero sí la correspondiente al pago por reivindicación adicional.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Única No. 10 de 2001.

JOSÉ LUIS SALAZAR LÓPEZ
Director de Nuevas Creaciones (c)

El anterior requerimiento fue notificado por fijación en lista, de fecha 2013-09-03

Elaboró: Lenin Roberto Guerrero
Revisó: Consuelo Leguizamon Leguizamon

2-Arylbenzimidazoles as Antiviral and Antiproliferative Agents-Part 1

G. Vitale[a], A. Carta[a], M. Loriga[a], G. Paglietti[a,*], P. La Colla[b,*], B. Busonera[b], D. Collu[b] and R. Loddo[b]

[a]*Dipartimento Farmaco Chimico Tossicologico, Università di Sassari, Via Muroni,23-07100 Sassari (Italy);* [b]*Dipartimento di Scienze e Tecnologie Biomediche, Sezione di Microbiologia e Virologia Generale e Biotecnologie Microbiche, Università di Cagliari; Cittadella Universitaria, 09042 Monserrato (CA), Italy*

Abstract: Being involved in an anti-Flaviviridae Project, and because of the role played by benzimidazole derivatives as promising inhibitors of the HCV helicase and RNA polymerase, as well as of the Zn finger transcription factor, we synthesized a new series of 2-arylbenzimidazoles and evaluated them for antiviral activity, as well as for antiproliferative activity.

Compounds were tested in cell-based assays against viruses representative of: i) two of the three genera of the *Flaviviridae* family, i.e. *Flaviviruses* and *Pestiviruses*; ii) other RNA virus families, such as *Retroviridae, Picornaviridae, Paramyxoviridae, Rhabdoviridae and Reoviridae;* iii) two DNA virus families (*Herpesviridae and Poxviridae*). Compounds **15**, **28** and **29** resulted moderately active only against Yellow Fever Virus (a *Flavivirus*) (range 6-27 μM), whereas none of the title benzimidazoles showed any antiviral activity at concentrations not cytotoxic for the resting cell monolayers.

Compounds were also tested for antiproliferative activity against a panel of exponentially growing cell lines derived from human haematological and solid tumors. Several new benzimidazoles turned out active. Among them, compound **27** was the most potent against human haematologic and solid tumor cells and turned out to be as potent as Etoposide and more potent than 6-mercaptopurine (6-MP), used as reference antitumor agents.

Key Words: Antiviral activity, flaviviridae, antiproliferative activity, arylbenzimidazoles.

INTRODUCTION

Benzimidazoles represent a class of heterocycles which are receiving much interest in the field of anti-infective therapies. Up to 1980 the most extensively marketed benzimidazoles spanned from pharmaceuticals (mainly human and veterinary antihelmintic, a few antineoplastic, antihistaminic, vasodilator and psychoactive agents), insecticides to fungicides [1]. After 1980 benzimidazole derivatives have emerged as a new class of commercially successful antiulcer agents. Among these, Omeprazole (AstraZenecka) is still on the top ten worldwide marketed drugs. A special attention was dedicated to benzimidazole derivatives as promising antiviral agents [2].

Benzimidazole (**1**) (Fig. **1**), in fact, may be considered a 1,3-dideazapurine and may replace this base in the process involving formation of nucleosides in viral replication.

Variously benzene ring substituted benzimidazoles, bearing a carbocyclic ring at position 1 instead of a normal sugar, have been considered as nucleoside analogues of purines. For example, compounds of structure **2** are reported to be active against hepatitis B virus at 0.74 μM [3], while compound **3** exhibited an *in vitro* inhibiting activity against both DNA and RNA virus [2].

*Address correspondence to these authors at the Dipartimento Farmaco Chimico Tossicologico, *via* Muroni 23/a, 07100 Sassari, Italy; Tel: +39-079228704; Fax: +39-079-228720; E-mail: paglietti@uniss.it

Dipartimento di Scienze e Tecnologie Biomediche, Sezione di Microbiologia e Virologia Generale e Biotecnologie Microbiche, Università degli Studi di Cagliari, Cittadella Universitaria, 09042 Monserrato (Cagliari), Italy; E-mail: placolla@unica.it

1

1,3-dideazapurine or benzimidazole

Fig. (1). Structure of purine and benzimidazole (**1**).

Successively, compounds **4** and **5** revealed to be 100-fold more potent [4] against the same strain of virus (Fig. **2**).

However, emerging strategies using benzimidazole derivatives as antiviral agents broke through after the discovery of hepatitis C virus (HCV) and identification of its genome that took advantage of enormous efforts spent in both disclosing and fighting the HIV replication phases. Since chronic infections with hepatitis C virus is a serious worldwide public health problem, the demand for effective HCV antiviral therapeutics is at present very high. Thus, a recent review has defined the status of the research in this field, where benzimidazole derivatives play an important role as promising anti-HCV agents [5]. Viropharma patented a series of compounds of formula **6-9** as inhibitors of NS3 helicase, with IC_{50} ranging from 0.7-10 μM [6] (Fig. **3**).

Two similar series of benzimidazole derivatives were patented independently by Japan Tobacco, Bristol-Meyers-Squibb and among these compounds **10** [7] and **11** [8] were reported as strong inhibitors of NS5B RNA polymerase. More recently, Japanese Authors described compound **12** [9]

1573-4064/08 $55.00+.00 © 2008 Bentham Science Publishers Ltd.



Fig. (2). Benzimidazoles active as antiviral agents.

as an improvement of this type of NS5B RNA polymerase inhibitors (Fig. **4**).

Our interest in the description of the biological and pharmacological properties of benzimidazoles started long time ago, when we reported analgesic-antinflammatory [10, 11] and choleretic [12,13] activities, as well as a chloropromazine-like activity in the conditioned avoidance response [14,15]. In the last five years several teams coordinated by one of us (P. La Colla) have been involved in a national MIUR program aimed at the development of novel anti-HCV agents. Within this project, two groups belonging to different Universities (Genova and Sassari, Italy) jointly afforded a program for the preparation of HCV non-nucleoside inhibitors based on the benzimidazole structure. Thus, taking into account the recent disclosure of their activity as inhibitors of



Fig. (3). Benzimidazoles patented as inhibitors of NS3 helicase.



Fig. (4). Benzimidazoles patented as NS5B RNA polymerase inhibitors.

the HCV helicase and RNA polymerase [6-9], our group considered that part of this program could be oriented towards a further development of the benzimidazoles chemistry.

In this context, two convergent strategies were developed. On the one hand, we synthesized compounds of structure **A** (Fig. **5**), derived from a series previously described by Sparatore *et al.* [10,11,14,15] of which we designed homologues of 2-phenylbenzimidazoles by inserting, at position 2, "spacers" such as a 4'-substitued-diphenyle, a -styryl substituent or, simply, an α-naphtyl group. On the other hand, we extended the series of 5(6)-substitued–(1*H*) or 1-alky-2-benzyl and/or 2-phenylbenzimidazoles developed at the Genova University by Boido *et al.* [16], by synthesizing the compounds of structure B (Fig. **5**).



Fig. (5). General Structure of the designed drugs.

In this paper we report the preparation and the biological activity of compounds **13-36** of Fig. (**6**), as part of the above described program, in order to select novel potential leads against the cited targets and discover a possible antiproliferative activity. The naphtylbenzimidazoles are new compounds and represent the simplest case of homologation of 2-phenylbenzimidazoles. The effect of a bulkier substituent at position 2 of heteroring has not been so far considered in this class of compounds and the extra phenyl ring might result oriented preferentially towards or against the most prototropic stable imidazole form. Conformational analysis of compound **13**, using montecarlo method, confirms that three minima were obtained and the two rings are not coplanar. At the lowest energies the naphtyl group is almost planar as shown in Fig. (**7**).

It is worth noting that compound **13** has been recently described as an example of a small-molecule switch for zinc finger transcription factor and its inhibitory activity has been reported [17]. Because of the above indication, we deemed important to check whether any antiproliferative activity might be shown by derivatives with this particular structure.

CHEMISTRY

The preparation of 2-[naphtalen-1-yl]-1*H*-benzimidazoles (**13-36**) has been accomplished according to Scheme (**1**).

The diamines **a-f** were condensed with bisulphite compounds **g** and **h** according to the procedure described by Ridley *et al.* [18] to give the desired derivatives **13-24** in good yield (Table **1**). The nitro derivatives **19-24** were in turn converted into amines by reduction with hydrazine in the presence of palladium as catalyst. The primary amines **25-30** were then acetylated with acetic anhydride. The yields recorded in the last steps were from very high to moderate. Elucidation of the structures of prepared compounds were achieved by the whole of the elemental analyses and spectro-



13-36

Compd.	R	R_1	R_2
13	H	H	H
14	CH_3	H	H
15	CH_3	CH_3	H
16	Cl	H	H
17	Cl	Cl	H
18	CF_3	H	H
19	H	H	NO_2
20	CH_3	H	NO_2
21	CH_3	CH_3	NO_2
22	Cl	H	NO_2
23	Cl	Cl	NO_2
24	CF_3	H	NO_2
25	H	H	NH_2
26	CH_3	H	NH_2
27	CH_3	CH_3	NH_2
28	Cl	H	NH_2
29	Cl	Cl	NH_2
30	CF_3	H	NH_2
31	H	H	$NHCOCH_3$
32	CH_3	H	$NHCOCH_3$
33	CH_3	CH_3	$NHCOCH_3$
34	Cl	H	$NHCOCH_3$
35	Cl	Cl	$NHCOCH_3$
36	CF_3	H	$NHCOCH_3$

Fig. (6). General formula of the compounds synthesized.

scopic data (Table **1**). From the spectroscopic point of view it is interesting to note the differences existing in the UV spectra between the analogues 2-phenyl-1*H*-benzimidazoles described by some of us [13] and the 2-naphtyl derivatives of Table (**1**). 2-Phenylbenzimidazoles possess fine structure whereas the presence of a naphtyl ring at the same position causes the appearance of a broad intense band in the range of 309-289 nm for **13-18** and 327-306 nm for **30-36.** In the case of 2-[4-nitronaphtalen-1-yl]-*1H*-benzimidazoles (**19-24**) the maxima descend to a flat band at higher wavelength 358-323 nm because of conjugation with the nitro group. Compounds (**25-28**) exhibited three set of maxima around 332-325, 284-279 and 234-232 nm, while in compounds **29** and **30** the



Fig. (7). Energy minimization profile of compound **13**.

band around 280 nm decreases and the most intense band is batochromically shifted at 342 nm.

RESULTS AND DISCUSSION

As reported in Table (**2**), title compounds were evaluated *in vitro* against ssRNA$^+$ viruses representative of the *Flaviviridae* and *Picornaviridae* families. In particular, viruses representative of two of the three genera of the *Flaviviridae* family, [i.e., YFV (*Flaviviruses*) and BVDV (*Pestiviruses*), as HCV (*Hepacivirus*) can hardly be used in routine cell based assays], and of one genus of the *Picornaviridae* family [CVB-2 and Polio 1 (*Enteroviruses*)] were tested. Compounds were also tested against an additional ssRNA$^+$ virus [Human immunodeficiency virus (HIV-1)], and representatives of dsRNA viruses [*Reoviridae* (Reo-1)] and ssRNA$^-$ viruses, *Paramyxo* [respiratory syncytial virus (RSV)] and *Rhabdo* [vesicular stomatitis virus (VSV)]. Two representatives of DNA virus families were also included: HSV-1 (*Herpesviridae*) and VV (*Poxviridae*).

As far as the antiviral activity is concerned, compounds **15**, **28** and **29** resulted moderately active against the sole YFV (range 6-27 μM). In particular, against this virus **15** resulted only 6-fold less potent than the reference nucleoside analogue 2'-C-Me-guanosine (NM108). The other benzimidazole derivatives showed activity neither against HIV-1, nor against representatives of dsRNA (Reo) and ssRNA$^-$ viruses (RSV or VSV) (data not shown) at not cytotoxic concentrations.

The benzimidazole derivatives (**15, 16, 18, 21, 22, 24, 27, 28, 30, 33, 34, 36)** which showed some cytotoxicity for resting cell monolayers were evaluated against a panel of exponentially growing human cell lines derived from haematological (CCRF-CEM, WIL-2NS and CCRF-SB) (Table **3**) or solid tumours (SK-MEL-28, MCF7, SK-MES-1, HepG2 and DU145) (Table **4**). They were also evaluated against cell lines (MRC-5 and CRL7065) derived from normal human tissues (Table **5**). In these assays, etoposide and 6-mercaptopurine (6-MP) were used as reference drugs.

The data reported in Tables (**3-5**) show that compound **27** was the most active against both haematological and solid



i) refluxing ethanol; ii) hydrazine hydrate, 10% Pd/C; iii) acetic anhydride at 100 °C, 15 min.

Scheme (1). Synthesis of 5-mono- or 5,6-di- substituted -2-(4-R_2-naphtyl-1-yl)-1*H*-benzimidazoles (**13-36**).

tumour cells, resulting as potent as etoposide and more potent than 6-MP against all the exponentially growing cell lines tested.

In the series of compounds examined it seems evident that substituents in both benzimidazole and naphthalene rings affect cytotoxicity. In the set of compounds which are unsubstituted at the 4' position of the naphthalene moiety, the presence of two methyl electron-releasing groups at positions 5 and 6 of the heterocycle (compound **15**) strongly influence the activity (0.06 µM), which is equivalent to that of compound **27,** bearing an amino group at 4' position. The nitro-precursor **21** is 5-fold less potent, while its acetyl derivative (**32**) is 26-fold less potent. Among the other substituents at the benzimidazole ring, the dichloro and trifluoromethyl groups are the least cytotoxic. This behaviour was also observed in the antiproliferative activity (Tables **3** and **4**).

EXPERIMENTAL SECTION

General Remarks

Melting points were carried out with a Köfler hot stage or Digital Electrothermal melting point apparatus and are uncorrected. Infrared spectra were recorded as nujol mulls on NaCl plates with a Perkin-Elmer 781 IR spectrophotometer and are expressed in ν (cm^{-1}). UV spectra are qualitative and were recorded in nm for solutions in EtOH with a Perkin-Elmer Lamba 5 spectrophotometer. Nuclear magnetic resonance (^{1}H-NMR) spectra were determined in $CDCl_3$, DMSO-d_6, $CDCl_3$/DMSO-d_6 (in the ratio 1:3) and were recorded in a Varian XL-200 (200 MHz). Chemical shifts (δ scale) are reported in parts per million (ppm) downfield from tetramethylsilane (TMS) as internal standard. Splitting patterns are designated, as follows: s, singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet; br s, broad singlet; dd, double doublets.

The assignment of exchangeable protons (OH and NH) was confirmed by the addition of D_2O. Analytical thin-layer chromatography (TLC) was performed on Merck silica gel F-254. Pure compounds showed a single spot in TLC. For flash chromatography, Merck silica gel 60 was used with a particle size 0.040-0.063 mm (230-400 mesh ASTM). Elemental analyses were performed on a Perkin-Elmer 2400 instrument at Laboratorio di Microanalisi, Dipartimento di Chimica, Università di Sassari, Italy, and results were within ±0.4% of theoretical values.

Chemistry

Intermediates

The diamines (**a-e)** were commercially available. The diamine (**f)** was prepared according to Walley [19] starting from the commercially available parent nitro compound (Aldrich). The bisulphite compounds (**h** and **g**) were obtained in high yields from the commercially available 1-naphtaldehyde and the purposely prepared 4-nitro-naphtalene-1-carbaldehyde following the procedure described by Katritzky and Xie [20].

General Procedure for Preparation of Compounds (13-24)

To a solution of 0.45 g (2.54-4.16 mmol) of the appropriate diamine (**a-f)** in ethanol (60 mL) was added in 1:1 molar ratio the sodium hydroxy(4-R_2-napht-1-yl)methanesulfonate (**h**,**g**). Then, the mixture was heated under reflux for 8 h. On cooling, a small amount of inorganic compound was filtered off and the ethanol mother liquors were evaporated to dryness in vacuo. The solid residues, coloured from white to

Table 1. Yields, Physical and Spectroscopic Data of Compounds of Scheme 1

Compd.	Yield %	M.p. °C	Analysis for	UV λ_{max}(EtOH) nm	IR ν_{max}(Nujol) cm^{-1}	^{1}H-NMR ($CDCl_3$-DMSO-d_6), *J* = Hz, δ:
13[22]	79	220-222	$C_{17}H_{12}N_2$	303, 224, 207	3344	8.79-8.75 (1H, m, H-8'), 8.04-7.94 (3H, m, arom.), 7.74 (5H, m, arom.), 7.34-7.28 (2H, m, arom.).
14	78	223-225	$C_{18}H_{14}N_2$	309, 222, 206	3346	8.83-8.78 (1H, m, H-8'), 8.01-7.91 (3H, m, arom.), 7.69-7.46 (5H, m, arom.), 7.11 (1H, d, *J* = 8.4; H-7), 2.51 (3H, s, 5-CH_3).
15	66	245-250	$C_{19}H_{16}N_2$	298, 205	3362	8.86-8.81 (1H, m, H-8'), 8.00-7.90 (3H, m, arom.), 7.78 (1H, s, H-4), 7.64-7.59 (3H, m, arom.), 7.45 (1H, s, H-7), 2,40 (6H, s, 5,6-CH_3).
16	81	138-140	$C_{17}H_{11}ClN_2$	(386, 377), 289, 248, 208	3351	8.75-8.72 (1H, m, H-8'), 8.00-7.89 (4H, m, arom.); 7.67-7.57 (4H, m, arom.); 7.24 (1H, dd, $J_{6,7}$ = 8,8, $J_{6,4}$ = 2,0, H-6), 6.63 (1H, m, arom.).
17	85	>300	$C_{17}H_{10}Cl_2N_2$	300, 208	3360	13.10 (1H, s, NH), 8.98-8.94 (1H, m, H-8'), 8.08 (1H, s, H-4), 8.04-7.92 (3H, m, arom.), 7.74 (1H, s, H-7), 7.69-7.50 (2H, m, arom.).
18	92	215-218	$C_{18}H_{11}F_3N_2$	290, 209	3361	8.88-8.84(1H, m, H-8'), 8.07-7.97 (4H, m, arom), 7.82-7.78 (1H, m, arom.), 7.68-7.51(4H, m, arom.).
19	76	289-291	$C_{17}H_{11}N_3O_2$	334, 222sh	1515	12.90 (1H, s, NH), 9.21-9.16 (1H, m, H-8'), 8.51-8.48 (1H, m, H-5'), 8.30 (1H, d, *J* = 7.9, H-2'), 8.08 (1H, d, J = 7.9, H-3'), 7.85-7.62 (4H, m, arom.), 7.33-7.29 (2H, m, arom.).
20	87	124-127	$C_{18}H_{13}N_3O_2$	349, 232sh	3319, 1506, 1329	8.21 (1H, d, *J* = 7.9, H-8'), 8.49 (1H, d, *J* = 7.9, H-5'), 8.29 (1H, d, *J* = 7.9, H-2'), 8.06 (1H, d, *J* = 8,0, H-3'), 7.83 (2H, m, H-6',7'), 6.51 (1H, d, *J* = 8.4, H-6), 7.49 (1H, s, H-4), 7.13 (1H, d, *J* = 8.2, H-7), 2.52 (3H, s, CH_3).
21	60	250-254	$C_{19}H_{15}N_3O_2$	358, 224sh	1516, 1337	9.03-8.99 (1H, m, H-8'), 8.53-8.49 (1H, m, H-5'), 8.19 (1H, d, *J* = 8.0, H-2'), 7,92 (1H, d, *J* = 8.0, H-3'), 7.78-7.42 (4H, m, arom.), 2.42 (6H, s, 5,6-CH_3).
22	73	122-125	$C_{17}H_{10}ClN_3O_2$	334, 224sh	1508, 1329	9.15-9.11 (1H, m, H-8'), 8.52-8.47 (1H, m, H-5'), 8.29 (1H, d, *J* = 8.2, H-2'), 8.07 (1H, d, *J* = 8.2, H-3'), 7.85-7.64 (4H, m, H-4,7,6',4'), 7.27 (1H, dd, $J_{6,7}$ = 8.6, $J_{6,4}$ = 2.0, H-6).
23	50	285-290	$C_{17}H_9Cl_2N_3O_2$	336, 232	3359, 1516, 1337	13.30 (1H, s, NH), 9.18-9.14 (1H, m, H-8'), 8.46-8.42 (1H, m, H-5'), 8.34 (1H, d, *J* = 7.6, H-2'), 8.13 (1H, s, H-4), 8.10 (1H, d, *J* = 7.6, H-3'), 8.02 (1H, s, H-7), 7.92-7.70 (2H, m, H-6'7').
24	66	121-123	$C_{18}H_{10}F_3N_3O_2$	330, 242sh, 205	1513, 1335	9.12-9.07 (1H, m, H-8'), 8.50 (1H, dd, $J_{6,7}$ = 8.6, $J_{4,6}$ = 1.6, H-6), 8.30 (1H, d, *J* = 8.6, H-2'), 8.09 (1H, d, *J* = 8.6, H-3'), 8.04 (1H, s, H-4), 7.85 (4H, m, arom.), 7.52 (1H, d, *J* = 8.4, H-7).

(Table 1. Contd….)

Compd.	Yield %	M.p. °C	Analysis for	UV λ_{max}(EtOH) nm	IR ν_{max}(Nujol) cm^{-1}	^{1}H-NMR ($CDCl_3$-DMSO-d_6), *J* = Hz, δ:
25	89	277-279	$C_{17}H_{13}N_3$	327, 280, 233	3443, 3366	8.98-8.94 (1H, m, H-8'), 8.10-8.03 (1H, m, H-5), 7.73-7.49 (5H, m, arom.), 7.30-7.20 (2H, m, arom.), 6.85-6.82 (1H, m, arom), 5.41 (2H, s, NH_2).
26	92	250-255	$C_{18}H_{15}N_3$	325, 280, 233	3453, 3343, 3160	8.62-8.56 (1H, m, H-8'), 7.66-7.62 (1H, m, H-5'), 7.50 (1H, d, *J* = 7,8, H-2'), 7.32-7.26 (4H, m, H-4,6,6',7'), 7.05 (1H, d, *J* = 7.9, H-3'), 6.49 (1H, d, *J* = 7.6, H-7), 4.57 (2H, s, NH_2), 2.45 (3H, s, CH_3).
27	83	224-226	$C_{19}H_{17}N_3$	327, 285, 235	3376	8.90-8.86 (1H, m, H-8'), 8.13-8.09 (1H, m, H-5'), 7.71 (1H, d, *J* = 8.0, H-2'), 7.60-7.44 (2H, m, arom.), 7.37 (2H, s, H-4,7), 6.83 (1H, d, *J* = 8,0, H-3'), 5.75 (2H, s, NH_2), 2.38 (6H, s, 5,6-CH_3).
28	83	222-225	$C_{17}H_{12}ClN_3$	332, 280, 233	3404, 3383, 3334	8.75-8.71 (1H, m, H-8'), 7.84-7.80 (1H, m, H-5'), 7.68-7.48 (3H, m, arom.), 7.30-7.18 (2H, m, arom.) 6.74-6.68 (2H, m, arom.), 4.41 (2H, s, NH_2).
29	90	295-300	$C_{17}H_{11}Cl_2N_3$	342, 234	3402, 3234	12.60 (1H, s, NH), 9.07 (1H, d, *J* = 8.4, H-8'), 8.13 (1H, d, *J* = 8.0, H-5'), 7.76 (1H, d, *J* = 8,0, H-2'), 7.63-7.43 (4H, m, arom.), 6.83 (1H, d, *J* = 8.0, H-3'), 5.92 (2H, s, NH_2).
30	90	228-230	$C_{18}H_{12}F_3N_3$	342, 248, 205	3460, 3374	8.75-8.71 (1H, m, H-8'), 7.84-7.80 (2H, m, arom.), 7.59-7.46 (6H, m, arom.), 6.70 (1H, d, *J* = 8.6, H-7), 4.44 (2H, s, NH_2).
31	75	>300	$C_{20}H_{14}N_2O$	307, 216	3263, 1660	10.04 (1H, s, NHCO), 9.09-9.04 (1H, m, H-8'), 8.27-8.22 (1H, m, H-5'), 8.00-7.95 (2H, m, arom.), 7.68-7.59 (4H, m, arom.), 7.27-7.22 (2H, m, arom.), 2.29 (3H, s, CH_3).
32	78	>300	$C_{21}H_{16}N_2O$	306, 214	3234, 1658, 1529	10.03 (1H, s, NHCO), 9.07-9.02 (1H, m, H-8'), 8.25-8.22 (1H, m, H-5'), 7.99-7.93 (2H, m, arom.), 7.62-7.52 (4H, m, arom.), 7.43 (1H, s, H-4), 7.07 (1H, d, *J* = 8.6, H-7), 2.50 (3H, s, CH_3), 2.29 (3H, s, CO-CH_3).
33	65	>300	$C_{22}H_{18}N_2O$	(388), 309, 211	3268, 1658, 1528	10.02 (1H, s, NHCO), 9.10-9.05 (1H, m, H-8'), 8.25-8.20 (1H, m, H-5'), 8.02 (1H, s, H-4), 7.92 (1H, s, H-7), 7.61-7.32 (4H, m, arom.), 2.39 (6H, s, 5,6-CH_3), 2.28 (3H, s, CO-CH_3).
34	70	>300	$C_{20}H_{13}ClN_2O$	(386), 308, 216	3239, 1660, 1529	10.02 (1H, s, NHCO), 9.10-9.02 (1H, m, H-8'), 8.28-8.20 (1H, m, H-5'), 7.99-7.95 (2H, m, arom.), 7.63-7.58 (3H, m, arom.), 7.26-7.18 (2H, m, arom.), 2.29 (3H, s, CH_3).
35	53	>300	$C_{20}H_{12}Cl_2N_2O$	328, 233, 209	1660, 1528	9.97 (1H, s, NHCO), 8.90-8.85 (1H, m, H-8'), 8.28-8.23 (1H, m, H-5'), 8.00 (1H, d, *J* = 8.2, H-2'), 7.93 (1H, d, *J* = 8,0, H-3'), 7.81 (2H, s, H-4,7), 7.64-7.59 (2H, m, H-6,7), 2.33 (3H, s, CH_3).
36	50	>300	$C_{21}H_{13}F_3N_2O$	326, 232, 205	1658, 1529	9.99 (1H, s, NHCO), 9.01-8.98 (1H, m, H-8'), 8.28-8.25 (1H, m, H-5'), 7.97-7.60 (6H, m, arom.), 7.50 (1H, d, *J* = 8.4, H-7), 2.32 (3H, s, CH_3).

dark brown, were purified by recrystallization from ethanol or methanol. Melting points, yields, analytical and spectroscopic data are reported in Table (**1**).

General Procedure for Preparation of Compounds (25-30)

To a solution of 0.36 g (1.0-1.24 mmol) of compounds (**19-24**) in ethanol (20 mL) was added an excess of hydrazine

Table 2. Antiviral Activity Against ssRNA$^+$ Viruses

Compd.	R	R_1	R_2	EC_{50} [μM]				
				[a]HIV-1	[b]BVDV	[c]YFV	[d]CVB-2	[d]Sb-1
13	H	H	H	>0.7	>4	>80	>100	>100
14	CH_3	H	H	>0.2	>0.4	>15	>60	>60
15	CH_3	CH_3	H	>0.06	>0.5	6	>2	>2
16	Cl	H	H	>0.3	>0.7	>13	>2	>2
17	Cl	Cl	H	>0.9	>2	>100	>100	>100
18	CF_3	H	H	>0.5	>1	>6	>75	>75
19	H	H	NO_2	>6	>20	>58	>100	>100
20	CH_3	H	NO_2	>6	>8	>18	>33	>33
21	CH_3	CH_3	NO_2	>0.3	>4	>9	>5	>4
22	Cl	H	NO_2	>1.7	>2.5	>14	>4	>4
23	Cl	Cl	NO_2	>5	>4	>6	>18	>18
24	CF_3	H	NO_2	>3	>6	>2.3	>22	>22
25	H	H	NH_2	>0.7	>2.4	>6	>20	>20
26	CH_3	H	NH_2	>0.2	>0.4	>26	>4	>4
27	CH_3	CH_3	NH_2	>0.06	>0.3	>3	>0.6	>0.6
28	Cl	H	NH_2	>0.3	>0.7	27	>1	>1
29	Cl	Cl	NH_2	>0.6	>0.7	16	>33	>33
30	CF_3	H	NH_2	>0.5	>0.8	>6	>20	>20
31	H	H	$NHCOCH_3$	>2	>100	>100	>100	>100
32	CH_3	H	$NHCOCH_3$	>2	>17	>53	>100	>100
33	CH_3	CH_3	$NHCOCH_3$	>1.6	>16	>21	>65	>65
34	Cl	H	$NHCOCH_3$	>1.8	>6	>17	>11	>11
35	Cl	Cl	$NHCOCH_3$	>2	>5	>54	>100	>100
36	CF_3	H	$NHCOCH_3$	>5	>7	>8	>40	>40
°AZT				0.01	§ND	ND	ND	ND
***NM108**				>100	4	1	30	35
^NM176				≥100	40	>100	25	23

[a]Compound concn. (μM) required to achieve 50% protection of MT-4 cells (CD4+ Human T-cells containing an integrated HTLV-1 genome) from the HIV-1-induced cytopathogenicity, as determined by the MTT method.

[b]Compound concn. (μM) required to achieve of MDBK cells from the BVDV-induced cytopathogenicity, as determined by the MTT method.

[c]Compound concn. (μM) required to achieve 50% protection of BHK (Kidney fibroblast) cells from the YFV- and Reo-induced cytopathogenicity, as determined by the MTT method.

[d]Compound concn. (μM) required to reduce the plaque number of CVB-2 and Sb-1 by 50% in Vero 76 monolayers.

°AZT. 3'-azido-thymidine

§ND. Not Determined

*2'-C-Me-guanosine

^2'-Ethynyl-cytidine

Variation among duplicate samples was less than 15%.

Table 3. Antiproliferative Activity Against Human Cells from Haemathologic Tumours

Compd.	[a]CC_{50} [μM]			
	MT-4	CCRF-CEM	WILS-2NS	CCRF-SB
15	0.06±0.04	0.6±0.3	1.2±0.2	0.7±0.05
16	0.3±0.01	0.5±0.1	0.05±0.7	0.7±0.05
18	0.5±0.1	1.2±0.1	1.8±0.7	1.0±0.01
21	0.3±0.02	2.4±0.05	2.8±0.4	2.0±0.1
22	1.7±0.2	2.7±0.4	2.4±0.2	2.2±0.05
24	3.0±0.1	4.7±0.7	5.9±0.6	3.9±0.3
27	0.06±0.05	0.2±0.05	0.4±0.03	0.2±0.05
28	0.3±0.01	0.5±0.1	0.9±0.2	0.6±0.1
30	0.5±0.1	0.9±0.05	0.8±0.05	0.8±0.05
33	1.6±0.4	4.8±1	8.7±2	5.0±0.9
34	1.8±0.6	3.7±0.3	7.0±0.3	3.9±0.3
36	5.0±0.1	15±1	15±0.2	12±0.5
Etoposide	0.09±0.01	0.09±0.01	0.2±0.05	0.08±0.03

[a]Compound concn. (μM) ±SD required to reduce the viable cell number of MT-4 cells (CD4+ Human T-cells containing an integrated HTLV-1 genome), CCRF-CEM (CD4+ human acute T-lymphoblastic leukaemia), WIL-2NS (human splenic B-lymphoblastoid cells) and CCRF-SB (human acute B-lymphoblastic leukaemia) by 50%, as determined by the MTT method.

hydrate (98%) (1.5 ml) in 1:1.25 molar ratio and the mixture was refluxed in the presence of 45 mg of 10% Pd charcoal for 1 h. The solution was then allowed to reach room temperature and the catalyst was removed by filtration through filter paper washed with ethanol. The mother liquors were evaporated in rotavapor under reduced pressure. Compounds **25-30** were obtained as coloured solids, which were purified by triturating with methanol.

Melting points, yields, analytical and spectroscopic data are reported in Table (**1**).

General Procedure for Preparation of Compounds (31-36)

A mixture formed by 0.1 g (3.00-3.9 mmol) of the amines (**25-30**) and acetic anhydride (3-4 mL) was kept under stirring at 80-100 °C for about 15 min. On cooling, the precipitate formed was collected and washed with diethyl ether. The acetyl derivatives (**31-36**) were obtained pure. Melting points, yields, analytical and spectroscopic data are reported in Table (**1**).

Biology

Compounds

Compounds were dissolved in DMSO at 100 mM and then diluted in cell culture medium so that the highest compound concentration used (100 μM) contains a DMSO concentration of 0.1% which, when used alone, is not cytotoxic for any of the cell lines used in this study.

Cells and Viruses

Cell lines were purchased from American Type Culture Collection (ATCC). The absence of mycoplasma contamination was checked periodically by the Hoechst staining method. Cell lines supporting the multiplication of RNA viruses were the following: $CD4^+$ human T-cells containing an integrated HTLV-1 genome (MT-4); Madin-Darby Bovine Kidney (MDBK); Baby Hamster Kidney (BHK-21); Monkey kidney (Vero 76) cells.

Cytotoxic / Antiproliferative Assays

For cytotoxicity tests, run in parallel with antiviral assays, MDBK, BHK and Vero 76 cells were resuspended in 96 multiwell plates at an initial density of $6x10^5$, $1x10^6$ and $5x10^5$ cells/mL, respectively, in maintenance medium, without or with serial dilutions of test compounds. Cell viability was determined after 48-96 hrs at 37 °C in a humidified CO_2 (5%) atmosphere by the MTT method. The cytotoxicity of test compounds for Vero 76 monolayers was determined by staining with the crystal violet dye and, after extensive washing, comparing the amount of dye (recovered with a 0.1% SDS solution) to that of untreated monolayers.

It is worth noting that, due to the high cell density needed for virus growth, all the above cell monolayers contained resting cells.

For antiproliferative evaluations, exponentially growing cells derived from human haematological tumors [$CD4^+$ human T-cells containing an integrated HTLV-1 genome (MT-

Table 4. Antiproliferative Activity Against Human Cells from Solid Tumors

Compd.	[a]CC_{50} [μM]				
	SK-MEL-28	MCF7	SK-MES-1	HepG2	DU145
15	8.7±1	17±3	7.4±2	11±1	7.5±0.5
16	51±2	37±2	2.3±0.3	7.7±0.5	2.8±0.5
18	3.1±0.1	4.2±0.5	3.2±0.1	6.5±2	4.3±0.2
21	10±3	7.2±0.6	9.7±0.9	8.3±0.8	7.2±2
22	11±1	7.2±0.4	11±0.2	8.6±0.5	6.1±0.9
24	8.8±0.1	9.5±0.6	8.8±0.7	10±1	7.7±0.5
27	1.0±0.05	0.7±0.1	0.9±0.04	1.1±0.1	0.9±0.05
28	2.9±0.5	2.8±0.3	2.6±0.8	3.3±0.05	2.2±0.3
30	1.9±0.2	2.1±0.2	1.9±0.1	2.8±0.3	1.9±0.2
33	34±4	56±7	34±4	>100	33±2
34	33±5	10±0.01	7.5±0.3	23±1	2.8±0.1
36	11±0.1	6.0±0.8	4.6±0.9	25±1	3.5±0.2
6-MP	15±2	3.2±1.2	>100	8.0±2.6	2.0±0.2
Etoposide	1.2±0.5	1.0±0.7	0.3±0.2	0.7±0.1	0.4±0.2

[a]Compound concn. (μM) ±SD required to reduce the viable cell number of SK-MEL-28 (skin melanoma), MCF-7 (breast adenocarcinoma), SK-MES-1 (lung squamous carcinoma), HepG2 (hepatocellular carcinoma) and DU-145 (prostate carcinoma) by 50%, as determined by the MTT method.

4); $CD4^+$ human acute T-lymphoblastic leukaemia (CCRF-CEM); Human splenic B-lymphoblastoid cells (WIL-2NS); Human acute B-lymphoblastic leukemia (CCRF-SB)] were seeded at an initial density of $1x10^5$ cells/ml in 96 well plates in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), 100 units/mL penicillin G and 100 μg/mL streptomycin. Human cell lines derived from solid tumours [skin melanoma (SK-MEL-28); breast adenocarcinoma (MCF-7); lung squamous carcinoma (SK-MES-1); hepatocellular carcinoma (HepG-2); prostate carcinoma (DU-145)] or normal tissues [lung fibroblasts (MRC-5); foreskin fibroblasts CRL-7065)] were also seeded at $1x10^5$ cells/ml in 96 well plates in the same specific media supplemented with 10% FCS and antibiotics as above. Cell cultures were then incubated at 37 °C in a humidified, 5% CO_2 atmosphere in the absence or presence of serial dilutions of test compounds. The extent of viable cell growth was determined after 96 hrs at 37 °C by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method [21]. It is worth noting that the effect of compounds on these cell lines was determined under experimental conditions allowing cells to undergo exponential growth for at least three cell cycles.

In conclusion, we will refer to the effect of compounds on the various cell lines as "cytotoxic" or "antiproliferative", according to whether the cells are resting or proliferating, respectively.

Antiviral Assays

Activity of compounds against Human Immunodeficiency virus type-1 (HIV-1) was based on inhibition of virus-induced cytopathogenicity in MT-4 cells acutely infected with a multiplicity of infection (m.o.i.) of 0.01. Briefly, 50 μL of RPMI containing $1x10^4$ MT-4 were added to each well of flat-bottom microtitre trays containing 50 μL of RPMI, without or with serial dilutions of test compounds. Then, 20 μL of an HIV-1 suspension containing 100 $CCID_{50}$ were added. After a 4-day incubation, cell viability was determined by the MTT method.

Activity of compounds against Yellow fever virus (YFV), 17D vaccine strain and Reo virus type-1 (Reo-1) was based on inhibition of virus-induced cytopathogenicity in acutely infected BHK-21 cells. Activities against Bovine viral diarrhoea virus (BVDV), in infected MDBK cells were also based on inhibition of virus-induced cytopathogenicity.

BHK and MDBK cells were seeded in 96-well plates at a density of $5x10^4$ and $3x10^4$ cells/well, respectively, and were allowed to form confluent monolayers by incubating overnight in growth medium at 37 °C in a humidified CO_2 (5%) atmosphere. Cell monolayers were then infected with 50 μL of a proper virus dilution (in serum-free medium) to give an m.o.i = 0.01. One hr later, 50 μL of MEM Earle's medium, supplemented with inactivated foetal calf serum (FCS), 1% final concentration, without or with serial dilutions of test compounds, were added. After a 3 day incubation at 37 °C, cell viability was determined by the MTT method.

Activity of compounds against Coxsackie virus, B-2 strain (CVB-2), Polio virus type-1 (Sb-1), Sabin strain, Vesicular Stomatitis Virus (VSV) and against Respiratory syncytial virus (RSV), A-2 strain, in infected Vero 76 cells, was

Table 5. Antiproliferative Activity Against Human Cells from Normal Tissues

Compd.	[a]CC_{50}[μM]	
	MRC-5	CRL7065
15	9.0±3	30±0.5
16	40±6	56±9
18	5.8±1	6.0±0.2
21	10±1	93±7
22	10±0.7	40±6
24	8.6±0.7	15±4
27	1.1±0.1	44±6
28	2.6±0.4	>100
30	2.7±0.7	5.0±2
33	41±5	83±5
34	32±1	>100
36	21±3	>100
6-MP	>100	>100
Etoposide	>100	>100

[a]Compound concn. (μM) ±SD required to reduce the viable cell number of MRC-5 (lung fibroblast) and CRL7065 (foreskin fibroblast) by 50%, as determined by the MTT method.

determined by plaque reduction assays in Vero 76 cell monolayers. To this end, Vero 76 cells were seeded in 24-well plates at a density of $2.5x10^5$ cells/well and were allowed to form confluent monolayers by incubating overnight in growth medium at 37 °C in a humidified CO_2 (5%) atmosphere. Then, monolayers were infected with 250 μL of proper virus dilutions to give 50-100 PFU/well. Following removal of unadsorbed virus, 500 μL of Dulbecco's modified Eagle's medium supplemented with 1% inactivated FCS and 0.75% methyl cellulose, without or with serial dilutions of test compounds, were added. Cultures were incubated at 37 °C for 2 (Sb-1 and VSV), 3 (CVB-2) or 5 days (RSV) and then fixed with PBS containing 50% ethanol and 0.8% crystal violet, washed and air-dried. Plaques were then counted. 50% effective concentrations (EC_{50}) were calculated by linear regression technique.

Received: 19 May, 2008 Revised: 01 September, 2008 Accepted: 18 September, 2008

Linear Regression Analysis

Viral and cell growth at each drug concentration was expressed as percentage of untreated controls and concentrations resulting in 50% (EC_{50} and CC_{50}) growth inhibition were determined by linear regression analysis.

AKNOWLEDGEMENT

This work was supported by grants from Italian FIRB [(RBNE01J3SK 001)] and Cybersar (MIUR, PON) Projects.

REFERENCES

[1] Preston, P.N. Benzimidazoles and Congeneric Tricyclic Compounds, (Part Two), in *The Chemistry of Heterocyclic Compounds*, Edited by Weissberber, A.; Taylor, E.C.; Wiley, J. Eds., Interscience: London- New York, **1980** and references cited therein.

[2] Wolf, M. in *Burger's Medicinal Chemistry*, 4th, Wiley, J.; Sons, **1979**, pp. 554-555 and references cited therein .

[3] Daluge, S. (Burroghs Wellcome Co), **1995**, U.S. Patent 5,399,580; *Chem. Abstr.,* **1995**, *123,* 257270n.

[4] Wolf, M. in *Burger's Medicinal Chemistry* 5th ed., Vol. 4, J. Wiley & Sons, **1997**, p. 542 and references cited therein.

[5] Tan, S.L.; Pause, A.; Shi, Y.; Sonenberg, N. *Nat. Rev. Drug Discov.*, **2002**, *1*, 867.

[6] a) Diana, G.D.; Bailey, T.R. (ViroPharma Inc.), **1997**, U.S. Patent 5,633,388; b) Diana, G.D.; Bailey, T.R.; Nitz, T.J. (ViroPharma Inc.), **1997**, WO 9736554; c) May Wang, Q.; Du, M.X.; Hockman, M.A.; Johnson, R.B.; Xin-Lai, S. *Drug Future*, **2000**, *25*, 933.

[7] Hashimoto, H.; Mizutani, K.; Yoshida, A. (Japan Tobacco Inc. Japan), **2003**, U.S. Patent 50,32; *Chem. Abstr*., **2003** ,*138*, 238181c.

[8] Priestley, E.S.; Decicco, C.P.; Hudyma, T.W.; Zheng, X. (Bristol-Meyers-Squibb Company), **2003**, PCT Int. Appl. WO 03 26,587; *Chem. Abstr.,* **2003**, *138*, 287673y.

[9] Hirashima, S.; Suzuki, T.; Ishida, T.; Noj,i S.; Yata, S.; Ando, I.; Komatsu, M.; Ikeda S.; Hashimoto H. *J. Med. Chem*., **2006**, *49*, 4721.

[10] Paglietti, G.; Sparatore, F. *Il Farmaco*, *Ed. Sci.*, **1972**, *27*, 335.

[11] Paglietti, G.; Boido, V.; Sparatore, F. *Il Farmaco*, *Ed.Sci.*, 1974, *30*, 505.

[12] Paglietti, G.; Sparatore, F. *Il Farmaco*, *Ed. Sci.*, **1972**, *27*, 471.

[13] Grella, G.; Paglietti, G.; Sparatore, F.; Manca, P.; Satta, M. *Il Farmaco*, *Ed.Sci*., **1987**, *42*, 475.

[14] Paglietti, G.; Pirisi, M.A.; Loriga, M.; Grella, G.; Sparatore, F.; Satta, M.; Manca, P.; Peana, A. *Il Farmaco*, *Ed.Sci*., **1988**, *43*, 203.

[15] Paglietti, G.; Pirisi, M.A.; Loriga, M.; Grella, G.; Sparatore, F.; Satta, M.; Manca, P. *Il Farmaco*, *Ed.Sci*., 1988, *43*, 215.

[16] Angusti, A.; Auzzas, L.; Boido, V.; Canu, C.; Carta, A.; Ciliberti, N.; Ferrone, M.; Loddo, R.; La Colla, P.; Loriga, M.; Manfredini, S.; Mazzei, M.; Nieddu, E.; Paglietti, G.; Panemi, M.S.; Pricl, S.; Rassu, G.; Sparatore, F.; Tasso, B.; Vitale, G. *Global Antiviral J.,* **2006**, *1*, 37.

[17] Lin, Q.; Barbas, C.F. 3rd; Schultz, P. G. *J. Am. Chem. Soc.,* **2003**, *125,* 612.

[18] Ridley, H.F.; Spickett, R.G.W.; Timmis, G.M, *J. Heterocycl. Chem*., **1965**, *2*, 453.

[19] Walley, V.B. *J. Chem. Soc.*, **1950**, 2792.

[20] Katritzky, A.R.; Xie, L. *Tethraedron Lett.,* **1996**, *37*, 347.

[21] Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyster, J.; De Clercq, E. *J. Virol. Methods*, **1988**, *20*, 309.

Copyright of Medicinal Chemistry is the property of Bentham Science Publishers Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.